Telomir Pharma Files 8-K on Agreements and Acquisitions
Ticker: TELO · Form: 8-K · Filed: Apr 24, 2026 · CIK: 0001971532
Sentiment: neutral
Topics: material-agreement, acquisition-disposition, equity-sale
TL;DR
Telomir Pharma dropped an 8-K detailing new deals and asset moves.
AI Summary
Telomir Pharmaceuticals, Inc. filed an 8-K on April 24, 2026, reporting on April 22, 2026, regarding a material definitive agreement, completion of an acquisition or disposition of assets, and unregistered sales of equity securities. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate actions by Telomir Pharmaceuticals, including potential new agreements and asset transactions, which could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements and asset transactions, which inherently carry business and financial risks.
Key Numbers
- 0001971532 — CIK Number (Identifies Telomir Pharmaceuticals, Inc. in SEC filings.)
- 2026-04-24 — Filing Date (Date the 8-K was officially filed with the SEC.)
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Filer of the 8-K report
- 0001971532 (company) — CIK number for Telomir Pharmaceuticals, Inc.
- 2026-04-24 (date) — Filing date of the 8-K
- 2026-04-22 (date) — Period of report for the 8-K
FAQ
What specific material definitive agreement was entered into by Telomir Pharmaceuticals, Inc. on or around April 22, 2026?
The filing indicates Item 1.01: Entry into a Material Definitive Agreement, but the specific details of the agreement are not provided in the summary text.
What acquisition or disposition of assets was completed by Telomir Pharmaceuticals, Inc. on or around April 22, 2026?
The filing indicates Item 2.01: Completion of Acquisition or Disposition of Assets, but the specifics of the transaction are not detailed in the provided text.
Were there any unregistered sales of equity securities by Telomir Pharmaceuticals, Inc. reported in this filing?
Yes, the filing lists Item 3.02: Unregistered Sales of Equity Securities as a reported item.
What is the business address of Telomir Pharmaceuticals, Inc.?
The business address is listed as 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131.
What is the primary SIC code for Telomir Pharmaceuticals, Inc.?
The primary SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 24, 2026 regarding Telomir Pharmaceuticals, Inc. (TELO).